Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29


Estrogen receptor-beta is a potential target for triple negative breast cancer treatment.

Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J.

Oncotarget. 2018 Sep 21;9(74):33912-33930. doi: 10.18632/oncotarget.26089. eCollection 2018 Sep 21.


Optimization Of Cancer Treatment Through Overcoming Drug Resistance.

Elshimali YI, Wu Y, Khaddour H, Wu Y, Gradinaru D, Sukhija H, Chung SS, Vadgama JV.

J Cancer Res Oncobiol. 2018;1(2). pii: 107. doi: 10.31021/jcro.20181107. Epub 2018 Feb 27.


Targeting of PP2Cδ By a Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo.

Wu K, Yu X, Huang Z, Zhu D, Yi X, Wu YL, Hao Q, Kemp KT 2nd, Elshimali Y, Iyer R, Nguyen KT, Zheng S, Chen G, Chen QH, Wang G, Vadgama JV, Wu Y.

Antioxid Redox Signal. 2018 Jul 13. doi: 10.1089/ars.2017.7486. [Epub ahead of print]


Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.

Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K.

Biochem Biophys Res Commun. 2018 Jun 7;500(3):621-625. doi: 10.1016/j.bbrc.2018.04.120. Epub 2018 Apr 30.


Angiolymphoid hyperplasia with eosinophilia: a case report.

Youssef A, Hasan AR, Youssef Y, Al-Soufi L, Elshimali Y, Alshehabi Z.

J Med Case Rep. 2018 Apr 2;12(1):89. doi: 10.1186/s13256-018-1599-x.


Insulin-Leptin Axis, Cardiometabolic Risk and Oxidative Stress in Elderly with Metabolic Syndrome.

Gradinaru D, Khaddour H, Margina D, Ungurianu A, Borsa C, Ionescu C, Prada GI, Usher J, Elshimali Y.

Exp Clin Endocrinol Diabetes. 2018 Feb 8. doi: 10.1055/s-0043-123825. [Epub ahead of print]


Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis.

Wu Y, Yu X, Yi X, Wu K, Dwabe S, Atefi M, Elshimali Y, Kemp KT 2nd, Bhat K, Haro J, Sarkissyan M, Vadgama JV.

Cancer Res. 2017 Mar 15;77(6):1383-1394. doi: 10.1158/0008-5472.CAN-16-2012. Epub 2017 Jan 23.


Lactate, a Neglected Factor for Diabetes and Cancer Interaction.

Wu Y, Dong Y, Atefi M, Liu Y, Elshimali Y, Vadgama JV.

Mediators Inflamm. 2016;2016:6456018. doi: 10.1155/2016/6456018. Epub 2016 Dec 18. Review.


Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy.

Wang P, Henning SM, Magyar CE, Elshimali Y, Heber D, Vadgama JV.

J Exp Clin Cancer Res. 2016 May 6;35:73. doi: 10.1186/s13046-016-0351-x.


Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array.

Chung S, Dwabe S, Elshimali Y, Sukhija H, Aroh C, Vadgama JV.

PLoS One. 2015 Aug 10;10(8):e0134948. doi: 10.1371/journal.pone.0134948. eCollection 2015.


Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.

Hamilton N, Márquez-Garbán D, Mah V, Fernando G, Elshimali Y, Garbán H, Elashoff D, Vadgama J, Goodglick L, Pietras R.

Biomed Res Int. 2015;2015:925703. doi: 10.1155/2015/925703. Epub 2015 Mar 22.


Slug contributes to cancer progression by direct regulation of ERα signaling pathway.

Li Y, Wu Y, Abbatiello TC, Wu WL, Kim JR, Sarkissyan M, Sarkissyan S, Chung SS, Elshimali Y, Vadgama JV.

Int J Oncol. 2015 Apr;46(4):1461-72. doi: 10.3892/ijo.2015.2878. Epub 2015 Feb 5.


Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R.

Crit Rev Oncog. 2015;20(5-6):373-90. doi: 10.1615/CritRevOncog.v20.i5-6.100. Review.


Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice.

Wu Y, Kim J, Elshimali Y, Sarkissyan M, Vadgama JV.

BMC Cancer. 2014 Apr 17;14:266. doi: 10.1186/1471-2407-14-266.


Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.

Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, Elshimali Y, Soslow RA, Penichet ML, Goodglick L, Wadehra M.

Mol Cancer Ther. 2014 Apr;13(4):902-15. doi: 10.1158/1535-7163.MCT-13-0199. Epub 2014 Jan 21.


Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.

Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV.

PLoS One. 2013 Oct 22;8(10):e78259. doi: 10.1371/journal.pone.0078259. eCollection 2013.


The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.

Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV.

Int J Mol Sci. 2013 Sep 13;14(9):18925-58. doi: 10.3390/ijms140918925. Review.


Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer.

Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV.

Am J Cancer Res. 2012;2(1):104-15. Epub 2011 Nov 21.


Higher levels of GATA3 predict better survival in women with breast cancer.

Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S, Mah V, Bose S, Chia D, Chang HR, Goodglick L.

Hum Pathol. 2010 Dec;41(12):1794-801. doi: 10.1016/j.humpath.2010.06.010.


Elevated MED28 expression predicts poor outcome in women with breast cancer.

Yoon NK, Maresh EL, Elshimali Y, Li A, Horvath S, Seligson DB, Chia D, Goodglick L.

BMC Cancer. 2010 Jun 28;10:335. doi: 10.1186/1471-2407-10-335.

Supplemental Content

Loading ...
Support Center